Literature DB >> 19012393

Assessment of additive/nonadditive effects in structure-activity relationships: implications for iterative drug design.

Yogendra Patel1, Valerie J Gillet, Trevor Howe, Joaquin Pastor, Julen Oyarzabal, Peter Willett.   

Abstract

Free-Wilson (FW) analysis is common practice in medicinal chemistry and is based on the assumption that the contributions to activity made by substituents at different substitution positions are additive. We analyze eight near complete combinatorial libraries assayed on several different biological response(s) (GPCR, ion channel, kinase and P450 targets) and show that only half-exhibit clear additive behavior, which leads us to question the concept of additivity that is widely taken for granted in drug discovery. Next, we report a series of retrospective experiments in which subsets are extracted from the libraries for FW analysis to determine the minimum attributes (size, distribution of substituents, and activity range) necessary to reach the same conclusion about additive/nonadditive effects. These attributes can provide guidelines on when it is appropriate to apply FW analysis as well as for library design, and they also have important implications for further steps in iterative drug design.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19012393     DOI: 10.1021/jm801070q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Molecular dynamics simulation and linear interaction energy study of D-Glu-based inhibitors of the MurD ligase.

Authors:  Andrej Perdih; Gerhard Wolber; Tom Solmajer
Journal:  J Comput Aided Mol Des       Date:  2013-08-30       Impact factor: 3.686

2.  Composite multi-parameter ranking of real and virtual compounds for design of MC4R agonists: renaissance of the Free-Wilson methodology.

Authors:  Ingemar Nilsson; Magnus O Polla
Journal:  J Comput Aided Mol Des       Date:  2012-10-02       Impact factor: 3.686

3.  Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y2 Receptor Based on AR-C118925.

Authors:  Sean Conroy; Nicholas D Kindon; Jacqueline Glenn; Leigh A Stoddart; Richard J Lewis; Stephen J Hill; Barrie Kellam; Michael J Stocks
Journal:  J Med Chem       Date:  2018-03-28       Impact factor: 7.446

4.  Predicting the points of interaction of small molecules in the NF-κB pathway.

Authors:  Yogendra Patel; Catherine A Heyward; Michael Rh White; Douglas B Kell
Journal:  BMC Syst Biol       Date:  2011-02-22

5.  Rationalizing tight ligand binding through cooperative interaction networks.

Authors:  Bernd Kuhn; Julian E Fuchs; Michael Reutlinger; Martin Stahl; Neil R Taylor
Journal:  J Chem Inf Model       Date:  2011-12-09       Impact factor: 4.956

6.  Nonadditivity in public and inhouse data: implications for drug design.

Authors:  D Gogishvili; E Nittinger; C Margreitter; C Tyrchan
Journal:  J Cheminform       Date:  2021-07-02       Impact factor: 5.514

7.  Strong nonadditivity as a key structure-activity relationship feature: distinguishing structural changes from assay artifacts.

Authors:  Christian Kramer; Julian E Fuchs; Klaus R Liedl
Journal:  J Chem Inf Model       Date:  2015-03-11       Impact factor: 4.956

8.  Current and emerging opportunities for molecular simulations in structure-based drug design.

Authors:  Julien Michel
Journal:  Phys Chem Chem Phys       Date:  2014-03-14       Impact factor: 3.676

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.